Sorafenib’s Survival Benefit in Advanced Hepatocellular Carcinoma
HCC patients who received sorafenib had significantly longer median survival and time to disease progression compared with those who received placebo.
Welcome to Journal Watch. The content you requested requires sign in with a username and password.
Sign In
Sign Up
Print subscribers
Activate your free online account for full access to all site content and features.
Other visitors
Subscribe for full access to all site content and features. ($99/year)
Purchase a site pass for full access to all articles. ($19/7 days)
Or, simply register for free access to email alerts, site features, and article archives. (FREE)